Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study

Autor: Yonemori, Kan, Boni, Valentina, Min, Kim Gun, Meniawy, Tarek M., Lombard, Janine, Kaufman, Peter A., Richardson, Debra L., Bender, Laura, Okera, Meena, Matsumoto, Koji, Giridhar, Karthik V., García-Sáenz, José Angel, Prenen, Hans, de Speville Uribe, Bernard Doger, Dizon, Don S., Garcia-Corbacho, Javier, Van Nieuwenhuysen, Els, Li, Yujia, Estrem, Shawn T., Nguyen, Bastien, Bacchion, Francesca, Ismail-Khan, Roohi, Jhaveri, Komal, Banda, Kalyan
Zdroj: In Gynecologic Oncology December 2024 191:172-181
Databáze: ScienceDirect
Externí odkaz: